Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Dec 13, 2024. (Total: 234352Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 12 (of 12 Records)

Query Trace: Neutropenia and CYP2C19[original query]
Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.
Cancer science 2005 Oct 96 (10): 721-8.
Yamada Yasuhide, Yamamoto Noboru, Shimoyama Tatsu, Horiike Atsushi, Fujisaka Yasuhito, Takayama Kyoko, Sakamoto Terumi, Nishioka Yuki, Yasuda Sanae, Tamura Tomohi
CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 May 13 (10): 2970-6.
Zandvliet Anthe S, Huitema Alwin D R, Copalu William, Yamada Yasuhide, Tamura Tomohide, Beijnen Jos H, Schellens Jan H
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Pharmacogenetics and genomics 2007 Jun 17 (6): 431-45.
Nakajima Miki, Komagata Sayaka, Fujiki Yuto, Kanada Yoshihiro, Ebi Hiromichi, Itoh Kuniaki, Mukai Hirofumi, Yokoi Tsuyoshi, Minami Hirono
Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.
Journal of human genetics 2009 Oct 54 (10): 564-71.
Low Siew-Kee, Kiyotani Kazuma, Mushiroda Taisei, Daigo Yataro, Nakamura Yusuke, Zembutsu Hitos
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Jun 24 (6): 1653-9.
Yamamoto N, Murakami H, Nishina T, Hirashima T, Sugio K, Muro K, Takahashi T, Naito T, Yasui H, Akinaga S, Koh Y, Boku
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
British journal of cancer 2013 Nov 109 (11): 2803-9.
Yamamoto N, Murakami H, Hayashi H, Fujisaka Y, Hirashima T, Takeda K, Satouchi M, Miyoshi K, Akinaga S, Takahashi T, Nakagawa
A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Investigational new drugs 2016 Dec .
Kyriakopoulos Christos E, Braden Amy M, Kolesar Jill M, Eickhoff Jens C, Bailey Howard H, Heideman Jennifer, Liu Glenn, Wisinski Kari
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
British journal of cancer 2017 Aug .
Lévi Francis, Karaboué Abdoulaye, Saffroy Raphaël, Desterke Christophe, Boige Valerie, Smith Denis, Hebbar Mohamed, Innominato Pasquale, Taieb Julien, Carvalho Carlos, Guimbaud Rosine, Focan Christian, Bouchahda Mohamed, Adam René, Ducreux Michel, Milano Gérard, Lemoine Antoinet
CYP2J27 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients.
Frontiers in pharmacology 2019 5 10 481.
Ahmed Jemal Hussien, Makonnen Eyasu, Yimer Getnet, Seifu Daniel, Bekele Abebe, Assefa Mathewos, Aseffa Abraham, Howe Rawleigh, Fotoohi Alan, Hassan Moustapha, Aklillu Ele
Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.
Pharmacology 2020 9 106 (3-4): 202-210.
Wang Xiaokang, Zhao Jingjing, Wen Ting, Liao Xueyi, Luo B
Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: Does UGT polymorphism affect these drug interactions?
Chemico-biological interactions 2022 Jul 364 110042.
Sangüesa Estela, Cirujeda Christine, Concha Julia, Padilla Pedro Pablo, García Cristina Belén, Ribate María Pil
The Effect of CYP2C19*2 (rs4244285) and CYP17 (rs743572) SNPs on Adriamycin and Paclitaxel based Chemotherapy Outcomes in Breast Cancer Patients.
Asian Pacific journal of cancer prevention : APJCP 2024 6 25 (6): 1977-1986.
Rashmi A Gudur, Suresh J Bhosale, Anand K Gudur, Shivani R Kale, Ashwini L More, Kailas D Datkhi
TOP